Ginkgo Bioworks (DNA)

Overall impact
A (86)

Commentary

Ginkgo Bioworks is a leader for overall positive impact. With an 'A' rating of 85.9 for overall impact (97th percentile compared to all companies), Ginkgo Bioworks ranks 5th out of 585 industry peers, behind Melinta Therapeutics, Genasys, Gamma Biosciences and 1 other, and ahead of Grifols, Biogen, Ionis Pharmaceuticals and 577 others. On top material causes for Ginkgo Bioworks's industry (Pharmaceuticals & Biotech), Ginkgo Bioworks performs well in Sustainable Use of Natural Resources (82.3 score), Child and Maternal Health (94.4), Reduced Green House Gas Emissions (95.1) and 8 other causes where it received an 'A' score. Ginkgo Bioworks did not receive a 'D' or 'F' rating on any cause.
Company
Founded
2008
Employees
485
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ma, United States
Share classes
DNA
Ginkgo Bioworks
Description
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Material causes
Ethos considers the following causes material for Ginkgo Bioworks, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.